The PDI-ATF6-axis as a novel treatment target in CSF3R driven chronic neutrophilic leukemia (CNL)
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1453
Abstract: Introduction CNL is a rare myeloproliferative neoplasm (MPN) with a 5-year-survival-rate of 28 percent, and no standard of care for treatment. The majority of CNL patients harbors the membrane proximal T618I mutation in the colony-stimulating… read more here.
Keywords: csf3r; treatment; csf3rt618i; activation ... See more keywords